Break it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA support

Stockhead TV’s Sarah Hughan brings you today’s Break it Down, detailing the US Government support for a knee osteoarthritis drug from Paradigm Biopharmaceuticals.

Stockhead's Break it Down brings you today's leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Paradigm Biopharmaceuticals' (ASX:PAR) support from the US Food and Drug Administration, paving the way for a pivotal clinical drug trial. 

Looking for alternative and equally innovative avenues to address unmet needs, Paradigm identified the potential of pentosan polysulfate sodium.

Tune in to get the latest.

While Paradigm Pharmaceuticals is a Stockhead advertiser, it did not sponsor this content.

Originally published as Break it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA support